What is CRISPR Therapeutics?
CRISPR Therapeutics is a gene editing therapeutics company company serving enterprise, commercial, consumer, healthcare, financial, real estate, or regulated-market customers.
- Category
- Gene editing therapeutics company
- Headquarters
- Zug, Switzerland
- Founded
- See official company history
- Employees
- See latest annual report and company filings
- Total funding
- Public company
- Status
- Public company; Nasdaq: CRSP
What is CRISPR Therapeutics?
CRISPR Therapeutics is a gene editing therapeutics company company headquartered in Zug, Switzerland. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
CRISPR Therapeutics is a gene editing therapeutics company company headquartered in Zug, Switzerland. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
For sellers, CRISPR Therapeutics should be mapped as a scaled public-company account. The best timing signals are earnings commentary, capital spending, hiring clusters, product launches, acquisitions, facility investments, and leadership changes.
What does CRISPR Therapeutics offer?
CRISPR Therapeutics's profile centers on Gene editing, Cell therapy, Hemoglobinopathies, Clinical development.
- Gene editing· Gene editing therapeutics company
- Cell therapy· Gene editing therapeutics company
- Hemoglobinopathies· Gene editing therapeutics company
- Clinical development· Gene editing therapeutics company
- CRISPR platform· Gene editing therapeutics company
- Partnered programs· Gene editing therapeutics company
How does CRISPR Therapeutics make money?
CRISPR Therapeutics makes money through commercial activity tied to gene editing therapeutics company.
CRISPR Therapeutics monetizes through the model common to gene editing therapeutics company: product sales, recurring services, contracts, leases, subscriptions, transaction volume, servicing, investment management, or usage depending on the operating unit.
Sales angles should connect to measurable priorities such as margin, growth, occupancy, compliance, retention, automation, risk reduction, data quality, customer experience, or field productivity.
Who leads CRISPR Therapeutics?
CRISPR Therapeutics's named executives should be verified on the official leadership or investor-relations page before outreach.
- CRISPR Therapeutics executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- CRISPR Therapeutics finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, capital allocation, and budget discipline.
- CRISPR Therapeutics operations or technology leadershipOperations, product, technology, security, or commercial leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operating-improvement purchases.
How do you contact CRISPR Therapeutics's leadership?
CRISPR Therapeutics should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://crisprtx.com- CRISPR Therapeutics investor relationsInvestor relations / corporate contactcontact via https://crisprtx.com
- CRISPR Therapeutics media relationsMedia or communications contact routecontact via https://crisprtx.com
How is CRISPR Therapeutics funded?
CRISPR Therapeutics's current status is Public company; Nasdaq: CRSP.
CRISPR Therapeutics's capital profile is best understood through its current public-company status: Public company; Nasdaq: CRSP. For public companies, financing and budget signals are usually found in annual reports, quarterly results, debt disclosures, buybacks, acquisitions, capital expenditure plans, and management commentary rather than venture funding rounds.
Before outreach, verify the latest status on the company's investor-relations page and current exchange filings.
How did CRISPR Therapeutics get here?
CRISPR Therapeutics's history should be read through founding, scale-up, public-market ownership, and current product or market focus.
- FoundingCRISPR Therapeutics is foundedThe company begins building in gene editing therapeutics company.
- Scale-upCommercial footprint expandsCRISPR Therapeutics broadens its product, customer, distribution, or geographic reach.
- Public marketsPublic company; Nasdaq: CRSPPublic-company ownership shapes reporting, procurement, and operating priorities.
- 2025Scaled operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, public-company status, and source references.
Who are CRISPR Therapeutics's competitors?
CRISPR Therapeutics competes with larger incumbents and focused specialists in gene editing therapeutics company.
CRISPR Therapeutics — frequently asked questions
